Effect of weak combined static and extremely low-frequency alternating magnetic fields on spatial memory and brain amyloid-β in two animal models of Alzheimer's disease

Electromagnetic Biology and Medicine
N V BobkovaEugenii E Fesenko

Abstract

Subchronic effect of a weak combined magnetic field (MF), produced by superimposing a constant component, 42 µT and an alternating MF of 0.08 µT, which was the sum of two frequencies of 4.38 and 4.88 Hz, was studied in olfactory bulbectomized (OBE) and transgenic Tg (APPswe, PSEN1) mice, which were used as animal models of sporadic and heritable Alzheimer's disease (AD) accordingly. Spatial memory was tested in a Morris water maze on the following day after completion of training trials with the hidden platform removed. The amyloid-β (Aβ) level was determined in extracts of the cortex and hippocampus of mice using a specific DOT analysis while the number and dimensions of amyloid plaques were detected after their staining with thioflavin S in transgenic animals. Exposure to the MFs (4 h/day for 10 days) induced the decrease of Aβ level in brain of OBE mice and reduced the number of Aβ plaques in the cortex and hippocampus of Tg animals. However, memory improvement was revealed in Tg mice only, but not in the OBE animals. Here, we suggest that in order to prevent the Aβ accumulation, MFs could be used at early stage of neuronal degeneration in case of AD and other diseases with amyloid protein deposition in other tissues.

References

Jan 1, 1986·Biological Psychiatry·M D WarnerJ R Tinklenberg
Apr 1, 1972·Physiology & Behavior·M H Sieck
Jan 1, 1981·International Review of Neurobiology·B E Leonard, M Tuite
Mar 1, 1995·The International Journal of Neuroscience·R Sandyk
Jan 1, 1997·Progress in Neuro-psychopharmacology & Biological Psychiatry·I V NesterovaN V Bobkova
Oct 8, 1999·The International Journal of Neuroscience·M A PersingerS A Koren
Sep 11, 2001·Bulletin of Experimental Biology and Medicine·N V BobkovaV V Nesterov
Sep 12, 2002·Bioelectromagnetics·E Del GiudiceG Talpo
Aug 23, 2003·Brain Research·Carol Ho-Wing Leung, Donald A Wilson
Mar 6, 2004·Biochemistry. Biokhimii︠a︡·I Yu AleksandrovaN V Bobkova
Sep 24, 2004·Proceedings of the National Academy of Sciences of the United States of America·V E KoliatsosK-X Huang
Apr 30, 2005·Biological Psychiatry·Hiske M van der SteltHerman G M Westenberg
Jun 1, 2005·Neuroscience and Biobehavioral Reviews·Cai Song, Brian E Leonard
Dec 30, 2006·Sozial- Und Präventivmedizin·Kerstin HugRegula Rapp
Jan 26, 2008·Biomagnetic Research and Technology·Livio GiulianiMikhail Zhadin
Feb 5, 2008·International Journal of Epidemiology·Ana M GarcíaSantiago Perez Hoyos
Jul 25, 2008·Nature·David M Holtzman
Sep 8, 2009·TheScientificWorldJournal·Beka Solomon
Jan 12, 2010·Journal of Alzheimer's Disease : JAD·Gary W ArendashChuanhai Cao
Oct 19, 2017·Biochemistry. Biokhimii︠a︡·N V GulyaevaN A Stefanova

❮ Previous
Next ❯

Citations

Apr 7, 2020·Health Physics·UNKNOWN International Commission on Non-Ionizing Radiation Protection (ICNIRP)

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.